modelLinezolid_1

Diagram of Linezolid_1

Extends from Pharmacolibrary.Drugs.ATC.J.J01XX08_1.

Information

name:Linezolid_1
ATC code:J01XX08_1
route:intravenous
compartments:2
dosage:600mg
volume of distribution:22.7L
clearance:7.5L/h
other parameters in model implementation

Linezolid is a synthetic antibiotic of the oxazolidinone class. It is primarily used to treat infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Linezolid is approved for clinical use and commonly prescribed for pneumonia, skin and soft tissue infections, and other severe bacterial infections.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers aged 18-55 years after single IV 600 mg dose, both sexes.

References

  1. Heidari, S, & Khalili, H (2023). Linezolid pharmacokinetics: a systematic review for the best clinical practice. European journal of clinical pharmacology 79(2) 195–206. DOI:10.1007/s00228-022-03446-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36565357

  2. Thibault, C, et al., & Autmizguine, J (2019). Population Pharmacokinetics of Intravenous Linezolid in Premature Infants. The Pediatric infectious disease journal 38(1) 82–88. DOI:10.1097/INF.0000000000002067 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29634620

  3. Sakurai, N, et al., & Kakeya, H (2022). Population pharmacokinetics of linezolid and its major metabolites PNU-142300 and PNU-142586 in adult patients. Pharmacotherapy 42(9) 707–715. DOI:10.1002/phar.2719 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35856168

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)